Company profile: Accent Therapeutics
1.1 - Company Overview
Company description
- Provider of biopharmaceutical oncology therapeutics developing first-in-class DHX9 inhibitors for cancers including those with BRCA loss and mismatch repair deficiencies; potential best-in-class KIF18A inhibitors for multiple indications including ovarian and triple-negative breast cancer; first-in-class small molecule ADAR1 inhibitors for solid tumors; and XRN1 inhibitors for tumors with higher IFN signaling, as monotherapies and with immuno-oncology therapeutics.
Products and services
- ADAR1 Inhibitors: Developing first-in-class small molecule inhibitors of ADAR1 for monotherapy use in solid tumor indications with significant unmet need
- DHX9 Inhibitor: A first-in-class inhibitor targeting DHX9 to treat cancers with high unmet need, including those with BRCA loss of function and mismatch repair deficiencies
- KIF18A Inhibitor: A potential best-in-class inhibitor for KIF18A designed to treat a broad patient population across several cancer indications, including ovarian and triple negative breast cancer
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Accent Therapeutics
Coordination Pharma
HQ: United States
Website
- Description: Provider of nanoparticle-based anticancer therapies, including CPI-100, which delivers immunostimulatory chemotherapeutic combinations directly to tumors. Offers the NCP platform using nanoscale coordination polymers to develop products targeting solid tumors, and seeks partnership opportunities to enhance current cancer immunotherapies.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coordination Pharma company profile →
CG Oncology
HQ: United States
Website
- Description: Provider of clinical-stage oncolytic immunotherapies targeting cancer, centered on the investigational agent cretostimogene grenadenorepvec for BCG-unresponsive non-muscle invasive bladder cancer (NMIBC). Activities include Phase 3 trials BOND-003 (monotherapy in high-risk BCG-unresponsive NMIBC) and PIVOT-006 (intermediate-risk NMIBC), and the Phase 2 CORE-001 combination with pembrolizumab in high-risk BCG-unresponsive NMIBC.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full CG Oncology company profile →
Nerio Therapeutics
HQ: United States
Website
- Description: Provider of biotechnology for the life sciences sector; founded in 2019 and based in La Jolla, CA, USA.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Nerio Therapeutics company profile →
NMS Group
HQ: Italy
Website
- Description: Provider of oncology research and development, managing the integrated R&D chain from pre-clinical to clinical stages. Operates a validated oncology drug discovery platform generating a pipeline of new chemical entities (NCEs).
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full NMS Group company profile →
Therapeutic Solutions International
HQ: United States
Website
- Description: Provider of biotechnology therapies and nutraceuticals, including JadiCell mesenchymal stem cell therapy for COVID-19 lung injury, COPD, and CTE; QuadraMune to enhance natural killer cell activity and immune support; StemVacs and StemVacs-V cancer immunotherapies; CampbellCell for psychiatric diseases; and FloraStilbene as an immunotherapy adjuvant.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Therapeutic Solutions International company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Accent Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Accent Therapeutics
2.2 - Growth funds investing in similar companies to Accent Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Accent Therapeutics
4.2 - Public trading comparable groups for Accent Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →